Utility of a Systolic Blood Pressure Polygenic Risk Score With Chlorthalidone Response
Authors' conclusion
In this genetic association study, Black individuals with HTN at a lower genetic risk of elevated BP experienced an approximately 3.5 mm Hg-greater response to chlorthalidone compared with those at an intermediate genetic risk of elevated BP. SBP PRS may also identify individuals with HTN harboring a higher risk of treatment-resistant HTN.
Study context
- Population
- Black Genetics of Hypertension Associated Treatments (GenHAT) participants aged ≥55 years with hypertension randomised to chlorthalidone or lisinopril, with genetic data availableor lisinopril 2,294
- Comparison
- Systolic BP (SBP) polygenic risk scores (PRS) quintiles and blood pressure (BP) response to chlorthalidone or lisinopril
- Primary endpoint
- Change in SBP (ΔSBP) and DBP (ΔDBP)
- Follow-up
- 6 months
Methodological detailsGenHAT ancillary pharmacogenomic genetic association study, independently validated
- GenHAT ancillary pharmacogenomic genetic association study
- Independently validated
Primary result
As reported in the abstract
ΔSBP with chlorthalidone
Lowest quintile
−10.01
mean · 95% CI −11.11–-8.90 · mm Hg
Median quintile
−6.57
mean · 95% CI −7.67–-5.48 · mm Hg
Further findings
| Outcome | OR (95% CI) | |
|---|---|---|
| aTRH (3 AHTs with uncontrolled HTN or ≥4 AHTs at year 3)Highest quintile vs Median quintile | 1.67 (1.19–2.36) | |
| 0.512Odds ratio (log scale) |
Original publication
Utility of a Systolic Blood Pressure Polygenic Risk Score With Chlorthalidone Response. JAMA Cardiol. Published 1 December 2024. doi:10.
Summarised from the published abstract; every number is checked against it